FiercePharmaOriginal article
{"a":[{"_":"FDA hits Lundbeck with untitled letter over efficacy claims on migraine drug Vyepti","$":{"href":"/marketing/fda-hits-lundbeck-untitled-letter-over-efficacy-claims-migraine-drug-vyepti","hreflang":"en"}}]}
RegulatoryVyeptiNegative
AI Analysis
Summary
The FDA issued an untitled letter to Lundbeck citing concerns over multiple efficacy claims for Vyepti listed on the company's healthcare provider webpage.
Outcome Details
FDA issued untitled letter regarding efficacy claims on healthcare provider webpage
Importance:5/10
Sentiment:
-0.70
FDAregulatory actionmarketing claimsuntitled lettermigraine
Related Companies
Read the original article
Published by FiercePharma on July 8, 2026 4:34 PM
